Kennedy Lucy Boyce, Salama April K S
Hematology/Oncology, Duke University, Durham, NC, USA.
Division of Medical Oncology, Duke University, Durham, NC, USA.
Oncol Ther. 2019 Dec;7(2):101-120. doi: 10.1007/s40487-019-0096-8. Epub 2019 Jul 8.
The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system can lead to a unique constellation of side effects, distinct from other cancer therapies, collectively termed immune-mediated adverse events (irAEs). This review will focus on irAEs and guidelines for management related to the most clinically relevant checkpoint inhibitors, those that target programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4).
基于检查点抑制剂的免疫疗法的应用已经改变了黑色素瘤以及许多其他癌症类型的治疗格局。这些药物能够增强肿瘤特异性免疫反应，从而实现持久的肿瘤控制。然而，免疫系统的这种激活会导致一系列独特的副作用，与其他癌症疗法不同，这些副作用统称为免疫介导的不良事件（irAEs）。本综述将聚焦于irAEs以及与临床上最相关的检查点抑制剂（即靶向程序性死亡受体-1（PD-1）和细胞毒性T淋巴细胞相关抗原4（CTLA-4）的抑制剂）相关的管理指南。
